drugset / Trial / NCT00334906

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

NCT00334906

Phase 4 Completed 75 enrolled Forest Laboratories
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the progression of disease using volumetric MRI techniques and cognitive outcome measures in patients with moderate dementia of the Alzheimer's type treated with open-label memantine.

Timeline

Start
2005-07
Primary completion
2007-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown

Indications